{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:02:28Z","timestamp":1789380148366,"version":"build-2803163510"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"DOI":"10.1038\/s41575-026-01257-x","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:03:27Z","timestamp":1789376607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Occult hepatitis B virus infection"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-3935","authenticated-orcid":false,"given":"Lung-Yi","family":"Mak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-7539","authenticated-orcid":false,"given":"Rex Wan-Hin","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-3035","authenticated-orcid":false,"given":"Teresa","family":"Pollicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9141-8001","authenticated-orcid":false,"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1257_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035 https:\/\/doi.org\/10.1038\/nrdp.2018.35 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","volume":"191","author":"BS Blumberg","year":"1965","unstructured":"Blumberg, B. S., Alter, H. J. & Visnich, S. A \u201cnew\u201d antigen in leukemia sera. JAMA 191, 541\u2013546 https:\/\/doi.org\/10.1001\/jama.1965.03080070025007 (1965).","journal-title":"JAMA"},{"key":"1257_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.211.2.261","volume":"211","author":"JH Walsh","year":"1970","unstructured":"Walsh, J. H., Purcell, R. H., Morrow, A. G., Chanock, R. M. & Schmidt, P. J. Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA 211, 261\u2013265 https:\/\/doi.org\/10.1001\/jama.211.2.261 (1970).","journal-title":"JAMA"},{"key":"1257_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.7326\/0003-4819-77-5-691","volume":"77","author":"HJ Alter","year":"1972","unstructured":"Alter, H. J. et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann. Intern. Med. 77, 691\u2013699 https:\/\/doi.org\/10.7326\/0003-4819-77-5-691 (1972).","journal-title":"Ann. Intern. Med."},{"key":"1257_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1046\/j.1537-2995.1979.19680104098.x","volume":"19","author":"E Tabor","year":"1979","unstructured":"Tabor, E. et al. Studies of donors who transmit posttransfusion hepatitis. Transfusion 19, 725\u2013731 https:\/\/doi.org\/10.1046\/j.1537-2995.1979.19680104098.x (1979).","journal-title":"Transfusion"},{"key":"1257_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/s0140-6736(88)92891-7","volume":"2","author":"V Thiers","year":"1988","unstructured":"Thiers, V. et al. Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 2, 1273\u20131276 https:\/\/doi.org\/10.1016\/s0140-6736(88)92891-7 (1988).","journal-title":"Lancet"},{"key":"1257_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/hep.1840120205","volume":"12","author":"TJ Liang","year":"1990","unstructured":"Liang, T. J., Blum, H. E. & Wands, J. R. Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology 12, 204\u2013212 https:\/\/doi.org\/10.1002\/hep.1840120205 (1990).","journal-title":"Hepatology"},{"key":"1257_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJM199907013410104","volume":"341","author":"I Cacciola","year":"1999","unstructured":"Cacciola, I. et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N. Engl. J. Med. 341, 22\u201326 https:\/\/doi.org\/10.1056\/NEJM199907013410104 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1257_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2020.05.042","volume":"73","author":"L-Y Mak","year":"2020","unstructured":"Mak, L.-Y. et al. Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance. J. Hepatol. 73, 952\u2013964 https:\/\/doi.org\/10.1016\/j.jhep.2020.05.042 (2020).","journal-title":"J. Hepatol."},{"key":"1257_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","volume":"71","author":"G Raimondo","year":"2019","unstructured":"Raimondo, G. et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 71, 397\u2013408 https:\/\/doi.org\/10.1016\/j.jhep.2019.03.034 (2019).","journal-title":"J. Hepatol."},{"key":"1257_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3350\/cmh.2022.0448","volume":"29","author":"L-Y Mak","year":"2023","unstructured":"Mak, L.-Y., Hui, R. W.-H., Fung, J., Seto, W. K. & Yuen, M.-F. The role of different viral biomarkers on the management of chronic hepatitis B. Clin. Mol. hepatol. 29, 263\u2013276 https:\/\/doi.org\/10.3350\/cmh.2022.0448 (2023).","journal-title":"Clin. Mol. hepatol."},{"key":"1257_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101487","volume":"7","author":"RW-H Hui","year":"2025","unstructured":"Hui, R. W.-H. et al. Profiles of HBV DNA integration in humans with hepatitis B virus infection: implications for antiviral treatment. JHEP Rep. 7, 101487 (2025).","journal-title":"JHEP Rep."},{"key":"1257_CR13","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany, M. G., Buti, M., Lampertico, P. & Lee, H. M. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology 78, 1654\u20131673 https:\/\/doi.org\/10.1097\/HEP.0000000000000431 (2023).","journal-title":"Hepatology"},{"key":"1257_CR14","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/apt.17690","volume":"58","author":"L-Y Mak","year":"2023","unstructured":"Mak, L.-Y. Editorial: HBsAg seroclearance after pegylated interferon treatment\u2014the beginning of the end. Aliment. Pharmacol. Ther. 58, 1103\u20131104 https:\/\/doi.org\/10.1111\/apt.17690 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1257_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/apt.17670","volume":"58","author":"N Gao","year":"2023","unstructured":"Gao, N. et al. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy. Aliment. Pharmacol. Ther. 58, 1086\u20131098 https:\/\/doi.org\/10.1111\/apt.17670 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1257_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3350\/cmh.2024.0724","volume":"31","author":"LY Mak","year":"2025","unstructured":"Mak, L.-Y. et al. Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters. Clin. Mol. Hepatol. 31, 460\u2013473 https:\/\/doi.org\/10.3350\/cmh.2024.0724 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1257_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep36464","volume":"6","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Prevalence of HBV DNA among 20 million seronegative blood donations in China from 2010 to 2015. Sci. Rep. 6, 36464 https:\/\/doi.org\/10.1038\/srep36464 (2016).","journal-title":"Sci. Rep."},{"key":"1257_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/gutjnl-2018-316490","volume":"68","author":"D Candotti","year":"2019","unstructured":"Candotti, D., Assennato, S. M., Laperche, S., Allain, J. P. & Levicnik-Stezinar, S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut 68, 313\u2013321 https:\/\/doi.org\/10.1136\/gutjnl-2018-316490 (2019).","journal-title":"Gut"},{"key":"1257_CR19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/gut.2010.209148","volume":"59","author":"MF Yuen","year":"2010","unstructured":"Yuen, M. F. et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut 59, 1389\u20131393 https:\/\/doi.org\/10.1136\/gut.2010.209148 (2010).","journal-title":"Gut"},{"key":"1257_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/liv.15233","volume":"42","author":"MS Franz\u00e8","year":"2022","unstructured":"Franz\u00e8, M. S., Pollicino, T., Raimondo, G. & Squadrito, G. Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases. Liver Int. 42, 963\u2013972 https:\/\/doi.org\/10.1111\/liv.15233 (2022).","journal-title":"Liver Int."},{"key":"1257_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","volume":"61","author":"T Pollicino","year":"2014","unstructured":"Pollicino, T., Cacciola, I., Saffioti, F. & Raimondo, G. Hepatitis B virus PreS\/S gene variants: pathobiology and clinical implications. J. Hepatol. 61, 408\u2013417 https:\/\/doi.org\/10.1016\/j.jhep.2014.04.041 (2014).","journal-title":"J. Hepatol."},{"key":"1257_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/gutjnl-2022-328380","volume":"72","author":"L Allweiss","year":"2023","unstructured":"Allweiss, L. et al. Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure. Gut 72, 972\u2013983 https:\/\/doi.org\/10.1136\/gutjnl-2022-328380 (2023).","journal-title":"Gut"},{"key":"1257_CR23","doi-asserted-by":"publisher","unstructured":"Takkenberg, R. B., Menting, S. & Beld, M. G. H. M. in\u00a0Diagnosis of Sexually Transmitted Diseases (eds MacKenzie, C. R. & Henrich, B.)\u00a0113\u2013128 https:\/\/doi.org\/10.1007\/978-1-61779-937-2_7 (Springer, 2012).","DOI":"10.1007\/978-1-61779-937-2_7"},{"key":"1257_CR24","first-page":"1513","volume":"124","author":"CH Xu","year":"2011","unstructured":"Xu, C. H. et al. Nested real-time quantitative polymerase chain reaction assay for detection of hepatitis B virus covalently closed circular DNA. Chin. Med. J. 124, 1513\u20131516 (2011).","journal-title":"Chin. Med. J."},{"key":"1257_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/hep.24551","volume":"54","author":"DK Wong","year":"2011","unstructured":"Wong, D. K. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54, 829\u2013836 https:\/\/doi.org\/10.1002\/hep.24551 (2011).","journal-title":"Hepatology"},{"key":"1257_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","volume":"69","author":"GP Caviglia","year":"2018","unstructured":"Caviglia, G. P. et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J. Hepatol. 69, 301\u2013307 https:\/\/doi.org\/10.1016\/j.jhep.2018.03.021 (2018).","journal-title":"J. Hepatol."},{"key":"1257_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05882-9","volume":"12","author":"S Hayashi","year":"2022","unstructured":"Hayashi, S. et al. Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application. Sci. Rep. 12, 2133 https:\/\/doi.org\/10.1038\/s41598-022-05882-9 (2022).","journal-title":"Sci. Rep."},{"key":"1257_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/hep.0000000000000843","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling, R. K. et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 81, 672\u2013724 https:\/\/doi.org\/10.1097\/hep.0000000000000843 (2025).","journal-title":"Hepatology"},{"key":"1257_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2022.105375","volume":"160","author":"DK Wong","year":"2023","unstructured":"Wong, D. K. et al. A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays. J. Clin. Virol. 160, 105375 https:\/\/doi.org\/10.1016\/j.jcv.2022.105375 (2023).","journal-title":"J. Clin. Virol."},{"key":"1257_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jhep.2020.03.009","volume":"73","author":"S Kusumoto","year":"2020","unstructured":"Kusumoto, S. et al. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J. Hepatol. 73, 285\u2013293 https:\/\/doi.org\/10.1016\/j.jhep.2020.03.009 (2020).","journal-title":"J. Hepatol."},{"key":"1257_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s1471-4914(02)02355-9","volume":"8","author":"D Klein","year":"2002","unstructured":"Klein, D. Quantification using real-time PCR technology: applications and limitations. Trends Mol. Med. 8, 257\u2013260 https:\/\/doi.org\/10.1016\/s1471-4914(02)02355-9 (2002).","journal-title":"Trends Mol. Med."},{"key":"1257_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29144","volume":"95","author":"MX Fu","year":"2023","unstructured":"Fu, M. X. et al. Ultrasensitive PCR system for HBV DNA detection: risk stratification for occult hepatitis B virus infection in English blood donors. J. Med. Virol. 95, e29144 https:\/\/doi.org\/10.1002\/jmv.29144 (2023).","journal-title":"J. Med. Virol."},{"key":"1257_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.70023","volume":"32","author":"RW-H Hui","year":"2025","unstructured":"Hui, R. W.-H. et al. Development and validation of a high-sensitivity droplet digital PCR assay for serum hepatitis B virus DNA detection. J. Viral Hepat. 32, e70023 https:\/\/doi.org\/10.1111\/jvh.70023 (2025).","journal-title":"J. Viral Hepat."},{"key":"1257_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422x-7-57","volume":"7","author":"D Paraskevis","year":"2010","unstructured":"Paraskevis, D. et al. Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA. Virol. J. 7, 57 https:\/\/doi.org\/10.1186\/1743-422x-7-57 (2010).","journal-title":"Virol. J."},{"key":"1257_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/apt.14376","volume":"47","author":"LY Mak","year":"2018","unstructured":"Mak, L.-Y. et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment. Pharmacol. Ther. 47, 43\u201354 https:\/\/doi.org\/10.1111\/apt.14376 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1257_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni, B. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70, 615\u2013625 https:\/\/doi.org\/10.1016\/j.jhep.2018.11.030 (2019).","journal-title":"J. Hepatol."},{"key":"1257_CR37","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/hep.31616","volume":"73","author":"LY Mak","year":"2021","unstructured":"Mak, L.-Y. et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 73, 2167\u20132179 https:\/\/doi.org\/10.1002\/hep.31616 (2021).","journal-title":"Hepatology"},{"key":"1257_CR38","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/hep.30082","volume":"68","author":"EK Butler","year":"2018","unstructured":"Butler, E. K. et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology 68, 2106\u20132117 https:\/\/doi.org\/10.1002\/hep.30082 (2018).","journal-title":"Hepatology"},{"key":"1257_CR39","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/HEP.0000000000000413","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany, M. G. et al. Use of HBV RNA and to predict change in serological status and disease activity in CHB. Hepatology 78, 1542\u20131557 https:\/\/doi.org\/10.1097\/HEP.0000000000000413 (2023).","journal-title":"Hepatology"},{"key":"1257_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","volume":"19","author":"A Kramvis","year":"2022","unstructured":"Kramvis, A. et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat. Rev. Gastroenterol. Hepatol. 19, 727\u2013745 https:\/\/doi.org\/10.1038\/s41575-022-00649-z (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1257_CR41","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jhep.2022.12.017","volume":"78","author":"C Adraneda","year":"2023","unstructured":"Adraneda, C. et al. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. J. Hepatol. 78, 731\u2013741 https:\/\/doi.org\/10.1016\/j.jhep.2022.12.017 (2023).","journal-title":"J. Hepatol."},{"key":"1257_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.108139","volume":"161","author":"F Zhan","year":"2025","unstructured":"Zhan, F. et al. The diagnostic value of hepatitis B core-related antigen in occult hepatitis B virus infection and its related hepatocellular carcinoma. Int. J. Infect. Dis. 161, 108139 https:\/\/doi.org\/10.1016\/j.ijid.2025.108139 (2025).","journal-title":"Int. J. Infect. Dis."},{"key":"1257_CR43","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/22221751.2022.2045874","volume":"11","author":"G Yu","year":"2022","unstructured":"Yu, G. et al. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerg. Microbes Infect. 11, 775\u2013785 https:\/\/doi.org\/10.1080\/22221751.2022.2045874 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"1257_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.14218\/jcth.2021.00051","volume":"9","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. B cell-mediated humoral immunity in chronic hepatitis B infection. J. Clin. Transl. Hepatol. 9, 592\u2013597 https:\/\/doi.org\/10.14218\/jcth.2021.00051 (2021).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1257_CR45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 83, 502\u2013583 https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018 (2025).","journal-title":"J. Hepatol."},{"key":"1257_CR46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","volume":"168","author":"FS Ali","year":"2025","unstructured":"Ali, F. S. et al. AGA clinical practice guideline on the prevention and treatment of hepatitis b virus reactivation in at-risk individuals. Gastroenterology 168, 267\u2013284 https:\/\/doi.org\/10.1053\/j.gastro.2024.11.008 (2025).","journal-title":"Gastroenterology"},{"key":"1257_CR47","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599 https:\/\/doi.org\/10.1002\/hep.29800 (2018).","journal-title":"Hepatology"},{"key":"1257_CR48","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"1257_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02983-1","volume":"23","author":"K Kan","year":"2023","unstructured":"Kan, K. et al. Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients \u2014 a retrospective longitudinal study. BMC Gastroenterol. 23, 348 https:\/\/doi.org\/10.1186\/s12876-023-02983-1 (2023).","journal-title":"BMC Gastroenterol."},{"key":"1257_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02140-w","volume":"20","author":"LK Lam","year":"2023","unstructured":"Lam, L. K. et al. Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy. Virol. J. 20, 168 https:\/\/doi.org\/10.1186\/s12985-023-02140-w (2023).","journal-title":"Virol. J."},{"key":"1257_CR51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","volume":"69","author":"HC Yang","year":"2018","unstructured":"Yang, H. C. et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J. Hepatol. 69, 286\u2013292 https:\/\/doi.org\/10.1016\/j.jhep.2018.02.033 (2018).","journal-title":"J. Hepatol."},{"key":"1257_CR52","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","volume":"7","author":"YR Im","year":"2022","unstructured":"Im, Y. R. et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 932\u2013942 https:\/\/doi.org\/10.1016\/S2468-1253(22)00201-1 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1257_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvh.13660","volume":"29","author":"DZ Ji","year":"2022","unstructured":"Ji, D. Z. et al. Global prevalence of occult hepatitis B: A systematic review and meta-analysis. J. Viral Hepat. 29, 317\u2013329 https:\/\/doi.org\/10.1111\/jvh.13660 (2022).","journal-title":"J. Viral Hepat."},{"key":"1257_CR54","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/liv.14473","volume":"40","author":"G Raimondo","year":"2020","unstructured":"Raimondo, G. et al. Occult hepatitis B virus infection predicts non-alcoholic steatohepatitis in severely obese individuals from Italy. Liver Int. 40, 1601\u20131609 https:\/\/doi.org\/10.1111\/liv.14473 (2020).","journal-title":"Liver Int."},{"key":"1257_CR55","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/s0168-8278(00)80134-8","volume":"33","author":"J Blackberg","year":"2000","unstructured":"Blackberg, J. & Kidd-Ljunggren, K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J. Hepatol. 33, 992\u2013997 https:\/\/doi.org\/10.1016\/s0168-8278(00)80134-8 (2000).","journal-title":"J. Hepatol."},{"key":"1257_CR56","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","volume":"135","author":"MF Yuen","year":"2008","unstructured":"Yuen, M.-F. et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 135, 1192\u20131199 https:\/\/doi.org\/10.1053\/j.gastro.2008.07.008 (2008).","journal-title":"Gastroenterology"},{"key":"1257_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10816-4","author":"Y Pan","year":"2025","unstructured":"Pan, Y., Jia, Z., Zhang, Y., Wu, Y. & Jiang, J. Estimates of the global prevalence of occult hepatitis B virus infection in population under 18 years old: a systematic review and meta-analysis. Hepatol. Int. https:\/\/doi.org\/10.1007\/s12072-025-10816-4 (2025).","journal-title":"Hepatol. Int."},{"key":"1257_CR58","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2012.04.021","volume":"57","author":"S Shahmoradi","year":"2012","unstructured":"Shahmoradi, S. et al. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J. Hepatol. 57, 515\u2013521 https:\/\/doi.org\/10.1016\/j.jhep.2012.04.021 (2012).","journal-title":"J. Hepatol."},{"key":"1257_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101158","volume":"29","author":"J Wu","year":"2024","unstructured":"Wu, J., He, J. & Xu, H. Global prevalence of occult HBV infection in children and adolescents: a systematic review and meta-analysis. Ann. Hepatol. 29, 101158 https:\/\/doi.org\/10.1016\/j.aohep.2023.101158 (2024).","journal-title":"Ann. Hepatol."},{"key":"1257_CR60","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s15010-024-02290-1","volume":"52","author":"A Eilard","year":"2024","unstructured":"Eilard, A., Andersson, M. E., Wejst\u00e5l, R., Norkrans, G. & Lindh, M. Occult hepatitis B infection in children born to HBeAg-positive women confers a low long-term risk for HBsAg-positive infection. Infection 52, 2351\u20132357 https:\/\/doi.org\/10.1007\/s15010-024-02290-1 (2024).","journal-title":"Infection"},{"key":"1257_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2022.01.030","volume":"77","author":"MW Lai","year":"2022","unstructured":"Lai, M. W. et al. Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan. J. Hepatol. 77, 63\u201370 https:\/\/doi.org\/10.1016\/j.jhep.2022.01.030 (2022).","journal-title":"J. Hepatol."},{"key":"1257_CR62","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/hep.21529","volume":"45","author":"T Pollicino","year":"2007","unstructured":"Pollicino, T. et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45, 277\u2013285 https:\/\/doi.org\/10.1002\/hep.21529 (2007).","journal-title":"Hepatology"},{"key":"1257_CR63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1172\/JCI116950","volume":"93","author":"TI Michalak","year":"1994","unstructured":"Michalak, T. I., Pasquinelli, C., Guilhot, S. & Chisari, F. V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J. Clin. Invest. 93, 230\u2013239 https:\/\/doi.org\/10.1172\/JCI116950 (1994).","journal-title":"J. Clin. Invest."},{"key":"1257_CR64","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/hep.20240","volume":"39","author":"MF Yuen","year":"2004","unstructured":"Yuen, M.-F. et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 39, 1694\u20131701 https:\/\/doi.org\/10.1002\/hep.20240 (2004).","journal-title":"Hepatology"},{"key":"1257_CR65","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/hep.23886","volume":"52","author":"M El Chaar","year":"2010","unstructured":"El Chaar, M., Candotti, D., Crowther, R. A. & Allain, J. P. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 52, 1600\u20131610 https:\/\/doi.org\/10.1002\/hep.23886 (2010).","journal-title":"Hepatology"},{"key":"1257_CR66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.antiviral.2013.11.015","volume":"102","author":"H Ding","year":"2014","unstructured":"Ding, H. et al. Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naive and lamivudine-treated patients with chronic hepatitis B. Antivir. Res. 102, 29\u201334 https:\/\/doi.org\/10.1016\/j.antiviral.2013.11.015 (2014).","journal-title":"Antivir. Res."},{"key":"1257_CR67","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2016.09.005","volume":"66","author":"KH Xiang","year":"2017","unstructured":"Xiang, K. H. et al. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. J. Hepatol. 66, 288\u2013296 https:\/\/doi.org\/10.1016\/j.jhep.2016.09.005 (2017).","journal-title":"J. Hepatol."},{"key":"1257_CR68","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jhep.2011.11.011","volume":"56","author":"M Bes","year":"2012","unstructured":"Bes, M. et al. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J. Hepatol. 56, 765\u2013774 https:\/\/doi.org\/10.1016\/j.jhep.2011.11.011 (2012).","journal-title":"J. Hepatol."},{"key":"1257_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1128\/JCM.01781-09","volume":"48","author":"Q Yuan","year":"2010","unstructured":"Yuan, Q. et al. Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. J. Clin. Microbiol. 48, 357\u2013362 https:\/\/doi.org\/10.1128\/JCM.01781-09 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"1257_CR70","doi-asserted-by":"publisher","first-page":"62706","DOI":"10.18632\/oncotarget.10909","volume":"7","author":"N Coppola","year":"2016","unstructured":"Coppola, N. et al. Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. Oncotarget 7, 62706\u201362714 https:\/\/doi.org\/10.18632\/oncotarget.10909 (2016).","journal-title":"Oncotarget"},{"key":"1257_CR71","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/jmv.21463","volume":"81","author":"Y Fang","year":"2009","unstructured":"Fang, Y. et al. Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. J. Med. Virol. 81, 826\u2013835 https:\/\/doi.org\/10.1002\/jmv.21463 (2009).","journal-title":"J. Med. Virol."},{"key":"1257_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139551","volume":"10","author":"H Kim","year":"2015","unstructured":"Kim, H., Gong, J. R., Lee, S. A. & Kim, B. J. Discovery of a novel mutation (X8Del) resulting in an 8-bp deletion in the hepatitis B virus X gene associated with occult infection in Korean vaccinated individuals. PLoS ONE 10, e0139551 https:\/\/doi.org\/10.1371\/journal.pone.0139551 (2015).","journal-title":"PLoS ONE"},{"key":"1257_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/hep.20748","volume":"42","author":"M Hass","year":"2005","unstructured":"Hass, M. et al. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 42, 93\u2013103 https:\/\/doi.org\/10.1002\/hep.20748 (2005).","journal-title":"Hepatology"},{"key":"1257_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-5-146","volume":"5","author":"FJ van Hemert","year":"2008","unstructured":"van Hemert, F. J., Zaaijer, H. L., Berkhout, B. & Lukashov, V. V. Occult hepatitis B infection: an evolutionary scenario. Virol. J. 5, 146 https:\/\/doi.org\/10.1186\/1743-422X-5-146 (2008).","journal-title":"Virol. J."},{"key":"1257_CR75","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/imr.12953","volume":"299","author":"AR Burton","year":"2021","unstructured":"Burton, A. R. & Maini, M. K. Human antiviral B cell responses: emerging lessons from hepatitis B and COVID-19. Immunol. Rev. 299, 108\u2013117 https:\/\/doi.org\/10.1111\/imr.12953 (2021).","journal-title":"Immunol. Rev."},{"key":"1257_CR76","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1053\/j.gastro.2008.02.017","volume":"134","author":"A Zerbini","year":"2008","unstructured":"Zerbini, A. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134, 1470\u20131481 https:\/\/doi.org\/10.1053\/j.gastro.2008.02.017 (2008).","journal-title":"Gastroenterology"},{"key":"1257_CR77","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","volume":"32","author":"WK Seto","year":"2014","unstructured":"Seto, W.-K. et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J. Clin. Oncol. 32, 3736\u20133743 https:\/\/doi.org\/10.1200\/JCO.2014.56.7081 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1257_CR78","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","volume":"128","author":"AR Burton","year":"2018","unstructured":"Burton, A. R. et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J. Clin. Invest. 128, 4588\u20134603 https:\/\/doi.org\/10.1172\/JCI121960 (2018).","journal-title":"J. Clin. Invest."},{"key":"1257_CR79","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest. 128, 4573\u20134587 https:\/\/doi.org\/10.1172\/JCI121957 (2018).","journal-title":"J. Clin. Invest."},{"key":"1257_CR80","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijid.2019.12.026","volume":"92","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Occurrence of occult hepatitis B virus infection associated with envelope protein mutations according to anti-HBs carriage in blood donors. Int. J. Infect. Dis. 92, 38\u201345 https:\/\/doi.org\/10.1016\/j.ijid.2019.12.026 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"1257_CR81","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41577-024-01097-3","volume":"24","author":"R Thimme","year":"2024","unstructured":"Thimme, R., Bertoletti, A. & Iannacone, M. Beyond exhaustion: the unique characteristics of CD8+ T cell dysfunction in chronic HBV infection. Nat. Rev. Immunol. 24, 775\u2013776 https:\/\/doi.org\/10.1038\/s41577-024-01097-3 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1257_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.850665","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Hepatitis B virus-specific cellular immunity contributes to the outcome of occult hepatitis B virus infection. Front. Microbiol. 13, 850665 https:\/\/doi.org\/10.3389\/fmicb.2022.850665 (2022).","journal-title":"Front. Microbiol."},{"key":"1257_CR83","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B Rehermann","year":"1996","unstructured":"Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F. V. The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104\u20131108 https:\/\/doi.org\/10.1038\/nm1096-1104 (1996).","journal-title":"Nat. Med."},{"key":"1257_CR84","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.29348","volume":"66","author":"X Cheng","year":"2017","unstructured":"Cheng, X. et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology 66, 1779\u20131793 https:\/\/doi.org\/10.1002\/hep.29348 (2017).","journal-title":"Hepatology"},{"key":"1257_CR85","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","volume":"137","author":"C Dunn","year":"2009","unstructured":"Dunn, C. et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137, 1289\u20131300 https:\/\/doi.org\/10.1053\/j.gastro.2009.06.054 (2009).","journal-title":"Gastroenterology"},{"key":"1257_CR86","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2017-314098","volume":"67","author":"H Li","year":"2018","unstructured":"Li, H. et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. Gut 67, 2035\u20132044 https:\/\/doi.org\/10.1136\/gutjnl-2017-314098 (2018).","journal-title":"Gut"},{"key":"1257_CR87","doi-asserted-by":"publisher","first-page":"e0187924","DOI":"10.1128\/jvi.01879-24","volume":"99","author":"Z Chen","year":"2025","unstructured":"Chen, Z. et al. APOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B\u00a0virus. J. Virol. 99, e0187924 https:\/\/doi.org\/10.1128\/jvi.01879-24 (2025).","journal-title":"J. Virol."},{"key":"1257_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100889","volume":"297","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. APOBEC3-induced mutation of the hepatitis virus B DNA genome occurs during its viral RNA reverse transcription into (\u2212)-DNA. J. Biol. Chem. 297, 100889 https:\/\/doi.org\/10.1016\/j.jbc.2021.100889 (2021).","journal-title":"J. Biol. Chem."},{"key":"1257_CR89","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","volume":"51","author":"M Levrero","year":"2009","unstructured":"Levrero, M. et al. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581\u2013592 https:\/\/doi.org\/10.1016\/j.jhep.2009.05.022 (2009).","journal-title":"J. Hepatol."},{"key":"1257_CR90","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1086\/529437","volume":"46","author":"P Vivekanandan","year":"2008","unstructured":"Vivekanandan, P., Kannangai, R., Ray, S. C., Thomas, D. L. & Torbenson, M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin. Infect. Dis. 46, 1227\u20131236 https:\/\/doi.org\/10.1086\/529437 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"1257_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/srep25901","volume":"6","author":"V Alarcon","year":"2016","unstructured":"Alarcon, V. et al. The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state. Sci. Rep. 6, 25901 https:\/\/doi.org\/10.1038\/srep25901 (2016).","journal-title":"Sci. Rep."},{"key":"1257_CR92","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/hep.29912","volume":"68","author":"JH Ren","year":"2018","unstructured":"Ren, J. H. et al. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatology 68, 1260\u20131276 https:\/\/doi.org\/10.1002\/hep.29912 (2018).","journal-title":"Hepatology"},{"key":"1257_CR93","doi-asserted-by":"publisher","first-page":"19975","DOI":"10.1073\/pnas.0908365106","volume":"106","author":"L Belloni","year":"2009","unstructured":"Belloni, L. et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl Acad. Sci. USA 106, 19975\u201319979 https:\/\/doi.org\/10.1073\/pnas.0908365106 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1257_CR94","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.antiviral.2018.03.008","volume":"153","author":"L Xu","year":"2018","unstructured":"Xu, L. et al. Tumor suppressor ZHX2 restricts hepatitis B virus replication via epigenetic and non-epigenetic manners. Antivir. Res. 153, 114\u2013123 https:\/\/doi.org\/10.1016\/j.antiviral.2018.03.008 (2018).","journal-title":"Antivir. Res."},{"key":"1257_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101215","volume":"12","author":"J Ren","year":"2025","unstructured":"Ren, J. et al. Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA. Genes. Dis. 12, 101215 https:\/\/doi.org\/10.1016\/j.gendis.2024.101215 (2025).","journal-title":"Genes. Dis."},{"key":"1257_CR96","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jhep.2005.06.016","volume":"44","author":"CJ Liu","year":"2006","unstructured":"Liu, C. J. et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J. Hepatol. 44, 39\u201346 https:\/\/doi.org\/10.1016\/j.jhep.2005.06.016 (2006).","journal-title":"J. Hepatol."},{"key":"1257_CR97","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14180","volume":"26","author":"M Dutch","year":"2024","unstructured":"Dutch, M., Cheng, A., Kiely, P. & Seed, C. Revised nucleic acid test window periods: applications and limitations in organ donation practice. Transpl. Infect. Dis. 26, e14180 https:\/\/doi.org\/10.1111\/tid.14180 (2024).","journal-title":"Transpl. Infect. Dis."},{"key":"1257_CR98","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/trf.12096","volume":"53","author":"JP Allain","year":"2013","unstructured":"Allain, J. P. et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 53, 1405\u20131415 https:\/\/doi.org\/10.1111\/trf.12096 (2013).","journal-title":"Transfusion"},{"key":"1257_CR99","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/trf.16543","volume":"61","author":"H Harvala","year":"2021","unstructured":"Harvala, H. et al. Hepatitis B infections among blood donors in England between 2009 and 2018: is an occult hepatitis B infection a risk for blood safety? Transfusion 61, 2402\u20132413 https:\/\/doi.org\/10.1111\/trf.16543 (2021).","journal-title":"Transfusion"},{"key":"1257_CR100","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/trf.18018","volume":"64","author":"MX Fu","year":"2024","unstructured":"Fu, M. X. et al. International review of blood donation screening for anti-HBc and occult hepatitis B virus infection. Transfusion 64, 2144\u20132156 https:\/\/doi.org\/10.1111\/trf.18018 (2024).","journal-title":"Transfusion"},{"key":"1257_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103095","volume":"81","author":"MX Fu","year":"2025","unstructured":"Fu, M. X. et al. Occult hepatitis B virus infection: risk for a blood supply, but how about individuals\u2019 health? eClinicalMedicine 81, 103095 https:\/\/doi.org\/10.1016\/j.eclinm.2025.103095 (2025).","journal-title":"eClinicalMedicine"},{"key":"1257_CR102","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/s0140-6736(94)90934-2","volume":"343","author":"O Chazouilleres","year":"1994","unstructured":"Chazouilleres, O. et al. \u201cOccult\u201d hepatitis B virus as source of infection in liver transplant recipients. Lancet 343, 142\u2013146 https:\/\/doi.org\/10.1016\/s0140-6736(94)90934-2 (1994).","journal-title":"Lancet"},{"key":"1257_CR103","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","volume":"52","author":"E Cholongitas","year":"2010","unstructured":"Cholongitas, E., Papatheodoridis, G. V. & Burroughs, A. K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J. Hepatol. 52, 272\u2013279 https:\/\/doi.org\/10.1016\/j.jhep.2009.11.009 (2010).","journal-title":"J. Hepatol."},{"key":"1257_CR104","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","volume":"81","author":"European Association for the Study of the Liver","year":"2024","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J. Hepatol. 81, 1040\u20131086 https:\/\/doi.org\/10.1016\/j.jhep.2024.07.032 (2024).","journal-title":"J. Hepatol."},{"key":"1257_CR105","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.transproceed.2004.12.041","volume":"37","author":"TM De Feo","year":"2005","unstructured":"De Feo, T. M. et al. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transpl. Proc. 37, 1238\u20131239 https:\/\/doi.org\/10.1016\/j.transproceed.2004.12.041 (2005).","journal-title":"Transpl. Proc."},{"key":"1257_CR106","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/00007890-199006000-00025","volume":"49","author":"C Feray","year":"1990","unstructured":"Feray, C. et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 49, 1155\u20131158 https:\/\/doi.org\/10.1097\/00007890-199006000-00025 (1990).","journal-title":"Transplantation"},{"key":"1257_CR107","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/s0168-8278(97)80035-9","volume":"26","author":"A Brind","year":"1997","unstructured":"Brind, A. et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J. Hepatol. 26, 228\u2013235 https:\/\/doi.org\/10.1016\/s0168-8278(97)80035-9 (1997).","journal-title":"J. Hepatol."},{"key":"1257_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2023.100348","volume":"9","author":"L Xu","year":"2023","unstructured":"Xu, L. et al. The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection. J. Virus Erad. 9, 100348 https:\/\/doi.org\/10.1016\/j.jve.2023.100348 (2023).","journal-title":"J. Virus Erad."},{"key":"1257_CR109","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1399-3062.2012.00782.x","volume":"14","author":"N Mahboobi","year":"2012","unstructured":"Mahboobi, N., Tabatabaei, S. V., Blum, H. E. & Alavian, S. M. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. Transpl. Infect. Dis. 14, 445\u2013451 https:\/\/doi.org\/10.1111\/j.1399-3062.2012.00782.x (2012).","journal-title":"Transpl. Infect. Dis."},{"key":"1257_CR110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.healun.2003.09.036","volume":"24","author":"SP Pinney","year":"2005","unstructured":"Pinney, S. P. et al. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J. Heart Lung Transpl. 24, 34\u201337 https:\/\/doi.org\/10.1016\/j.healun.2003.09.036 (2005).","journal-title":"J. Heart Lung Transpl."},{"key":"1257_CR111","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/TP.0000000000001769","volume":"101","author":"KL Lentine","year":"2017","unstructured":"Lentine, K. L. et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation 101, S7\u2013S105\u00a0https:\/\/doi.org\/10.1097\/TP.0000000000001769 (2017).","journal-title":"Transplantation"},{"key":"1257_CR112","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","volume":"68","author":"JR Wands","year":"1975","unstructured":"Wands, J. R., Chura, C. M., Roll, F. J. & Maddrey, W. C. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68, 105\u2013112 (1975).","journal-title":"Gastroenterology"},{"key":"1257_CR113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1056\/NEJM200101043440120","volume":"344","author":"I Dervite","year":"2001","unstructured":"Dervite, I., Hober, D. & Morel, P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 344, 68\u201369 https:\/\/doi.org\/10.1056\/NEJM200101043440120 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1257_CR114","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/hep.29022","volume":"65","author":"WK Seto","year":"2017","unstructured":"Seto, W.-K. et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 65, 1451\u20131461 https:\/\/doi.org\/10.1002\/hep.29022 (2017).","journal-title":"Hepatology"},{"key":"1257_CR115","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jhep.2019.08.023","volume":"72","author":"GL Wong","year":"2020","unstructured":"Wong, G. L. et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J. Hepatol. 72, 57\u201366 https:\/\/doi.org\/10.1016\/j.jhep.2019.08.023 (2020).","journal-title":"J. Hepatol."},{"key":"1257_CR116","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","volume":"80","author":"MH Chen","year":"2021","unstructured":"Chen, M. H. et al. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann. Rheum. Dis. 80, 1393\u20131399 https:\/\/doi.org\/10.1136\/annrheumdis-2021-220774 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1257_CR117","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3324\/haematol.2009.008607","volume":"94","author":"D Ritchie","year":"2009","unstructured":"Ritchie, D. et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94, 1618\u20131622 https:\/\/doi.org\/10.3324\/haematol.2009.008607 (2009).","journal-title":"Haematologica"},{"key":"1257_CR118","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMc063696","volume":"356","author":"J Grewal","year":"2007","unstructured":"Grewal, J., Dellinger, C. A. & Yung, W. K. Fatal reactivation of hepatitis B with temozolomide. N. Engl. J. Med. 356, 1591\u20131592 https:\/\/doi.org\/10.1056\/NEJMc063696 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1257_CR119","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jvh.12222","volume":"21","author":"X Huang","year":"2014","unstructured":"Huang, X. & Hollinger, F. B. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J. Viral Hepat. 21, 153\u2013162 https:\/\/doi.org\/10.1111\/jvh.12222 (2014).","journal-title":"J. Viral Hepat."},{"key":"1257_CR120","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1478-3231.2011.02481.x","volume":"32","author":"Y Shi","year":"2012","unstructured":"Shi, Y. et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 32, 231\u2013240 https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02481.x (2012).","journal-title":"Liver Int."},{"key":"1257_CR121","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1053\/jhep.2003.50171","volume":"37","author":"N Yuki","year":"2003","unstructured":"Yuki, N. et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37, 1172\u20131179 https:\/\/doi.org\/10.1053\/jhep.2003.50171 (2003).","journal-title":"Hepatology"},{"key":"1257_CR122","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/s0168-8278(00)00100-8","volume":"34","author":"I Chemin","year":"2001","unstructured":"Chemin, I. et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J. Hepatol. 34, 447\u2013454 https:\/\/doi.org\/10.1016\/s0168-8278(00)00100-8 (2001).","journal-title":"J. Hepatol."},{"key":"1257_CR123","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cgh.2019.06.029","volume":"18","author":"DK Wong","year":"2020","unstructured":"Wong, D. K. et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin. Gastroenterol. Hepatol. 18, 449\u2013456 https:\/\/doi.org\/10.1016\/j.cgh.2019.06.029 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1257_CR124","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/jmv.10514","volume":"71","author":"A Tamori","year":"2003","unstructured":"Tamori, A. et al. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J. Med. Virol. 71, 492\u2013498 https:\/\/doi.org\/10.1002\/jmv.10514 (2003).","journal-title":"J. Med. Virol."},{"key":"1257_CR125","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/gutjnl-2023-330414","volume":"73","author":"Z Qian","year":"2024","unstructured":"Qian, Z. et al. HBV integrations reshaping genomic structures promote hepatocellular carcinoma. Gut 73, 1169\u20131182 https:\/\/doi.org\/10.1136\/gutjnl-2023-330414 (2024).","journal-title":"Gut"},{"key":"1257_CR126","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.3748\/wjg.v11.i41.6416","volume":"11","author":"GC Kimbi","year":"2005","unstructured":"Kimbi, G. C., Kramvis, A. & Kew, M. C. Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B. World J. Gastroenterol. 11, 6416\u20136421 https:\/\/doi.org\/10.3748\/wjg.v11.i41.6416 (2005).","journal-title":"World J. Gastroenterol."},{"key":"1257_CR127","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ng.2295","volume":"44","author":"WK Sung","year":"2012","unstructured":"Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765\u2013769 https:\/\/doi.org\/10.1038\/ng.2295 (2012).","journal-title":"Nat. Genet."},{"key":"1257_CR128","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.dld.2020.10.007","volume":"53","author":"S Yang","year":"2021","unstructured":"Yang, S. et al. HBx acts as an oncogene and promotes the invasion and metastasis of hepatocellular carcinoma both in vivo and vitro. Dig. Liver Dis. 53, 360\u2013366 https:\/\/doi.org\/10.1016\/j.dld.2020.10.007 (2021).","journal-title":"Dig. Liver Dis."},{"key":"1257_CR129","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2003.10.048","volume":"126","author":"T Pollicino","year":"2004","unstructured":"Pollicino, T. et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126, 102\u2013110 https:\/\/doi.org\/10.1053\/j.gastro.2003.10.048 (2004).","journal-title":"Gastroenterology"},{"key":"1257_CR130","first-page":"1044","volume":"13","author":"TJ Liang","year":"1991","unstructured":"Liang, T. J. et al. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 13, 1044\u20131051 (1991).","journal-title":"Hepatology"},{"key":"1257_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11071011","volume":"11","author":"KE Bello","year":"2023","unstructured":"Bello, K. E. et al. A recent prevalence of hepatitis B virus (HBV) genotypes and subtypes in Asia: a systematic review and meta-analysis. Healthcare 11, 1011 https:\/\/doi.org\/10.3390\/healthcare11071011 (2023).","journal-title":"Healthcare"},{"key":"1257_CR132","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1128\/JCM.36.7.2084-2086.1998","volume":"36","author":"CM Chu","year":"1998","unstructured":"Chu, C. M., Yeh, C. T. & Liaw, Y. F. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J. Clin. Microbiol. 36, 2084\u20132086 https:\/\/doi.org\/10.1128\/JCM.36.7.2084-2086.1998 (1998).","journal-title":"J. Clin. Microbiol."},{"key":"1257_CR133","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001701","author":"S Lee","year":"2021","unstructured":"Lee, S., Yoon, H., Han, J. & Jang, K. L. Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection. J. Gen. Virol. https:\/\/doi.org\/10.1099\/jgv.0.001701 (2021).","journal-title":"J. Gen. Virol."},{"key":"1257_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57603-9","volume":"10","author":"K Murai","year":"2020","unstructured":"Murai, K. et al. Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Sci. Rep. 10, 941 https:\/\/doi.org\/10.1038\/s41598-020-57603-9 (2020).","journal-title":"Sci. Rep."},{"key":"1257_CR135","doi-asserted-by":"publisher","first-page":"710.e1","DOI":"10.1016\/j.cmi.2015.03.003","volume":"21","author":"SB Wiegand","year":"2015","unstructured":"Wiegand, S. B. et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-\u03b3-induced protein 10 levels in HBV\/HCV-coinfected patients. Clin. Microbiol. Infect. 21, 710.e1\u2013710.e9 https:\/\/doi.org\/10.1016\/j.cmi.2015.03.003 (2015).","journal-title":"Clin. Microbiol. Infect."},{"key":"1257_CR136","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2893.2005.00586.x","volume":"12","author":"S Momosaki","year":"2005","unstructured":"Momosaki, S., Nakashima, Y., Kojiro, M. & Tabor, E. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. J. Viral Hepat. 12, 325\u2013329 https:\/\/doi.org\/10.1111\/j.1365-2893.2005.00586.x (2005).","journal-title":"J. Viral Hepat."},{"key":"1257_CR137","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1590\/s0004-28032007000100013","volume":"44","author":"F Branco","year":"2007","unstructured":"Branco, F. et al. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arq. Gastroenterol. 44, 58\u201363 https:\/\/doi.org\/10.1590\/s0004-28032007000100013 (2007).","journal-title":"Arq. Gastroenterol."},{"key":"1257_CR138","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jmv.10566","volume":"72","author":"T Tanaka","year":"2004","unstructured":"Tanaka, T. et al. Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease. J. Med. Virol. 72, 223\u2013229 https:\/\/doi.org\/10.1002\/jmv.10566 (2004).","journal-title":"J. Med. Virol."},{"key":"1257_CR139","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM Mucke","year":"2018","unstructured":"Mucke, M. M. et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 3, 172\u2013180 https:\/\/doi.org\/10.1016\/S2468-1253(18)30002-5 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1257_CR140","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany, M. G., Morgan, T. R. & AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71, 686\u2013721 https:\/\/doi.org\/10.1002\/hep.31060 (2020).","journal-title":"Hepatology"},{"key":"1257_CR141","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/cid\/ciw507","volume":"63","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski, M. S. et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin. Infect. Dis. 63, 1202\u20131204 https:\/\/doi.org\/10.1093\/cid\/ciw507 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"1257_CR142","doi-asserted-by":"publisher","first-page":"867","DOI":"10.14309\/ajg.0000000000000588","volume":"115","author":"TT Chan","year":"2020","unstructured":"Chan, T. T. et al. Positive hepatitis B core antibody is associated with cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 115, 867\u2013875 https:\/\/doi.org\/10.14309\/ajg.0000000000000588 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1257_CR143","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","volume":"22","author":"SC Huang","year":"2024","unstructured":"Huang, S. C. et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin. Gastroenterol. Hepatol. 22, 581\u2013590.e6 https:\/\/doi.org\/10.1016\/j.cgh.2023.09.040 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1257_CR144","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak, L.-Y. et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J. Hepatol. 73, 800\u2013806 https:\/\/doi.org\/10.1016\/j.jhep.2020.05.040 (2020).","journal-title":"J. Hepatol."},{"key":"1257_CR145","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver,\u00a0European Association for the Study of Diabetes & European Association for the Study of Obesity.","year":"2024","unstructured":"European Association for the Study of the Liver,\u00a0European Association for the Study of Diabetes & European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031 (2024).","journal-title":"J. Hepatol."},{"key":"1257_CR146","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/MEG.0000000000001100","volume":"30","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients. Eur. J. Gastroenterol. Hepatol. 30, 682\u2013686 https:\/\/doi.org\/10.1097\/MEG.0000000000001100 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1257_CR147","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jmii.2019.04.009","volume":"53","author":"XX Chen","year":"2020","unstructured":"Chen, X. X. et al. Occult HBV infection in patients with autoimmune hepatitis: a virological and clinical study. J. Microbiol. Immunol. Infect. 53, 946\u2013954 https:\/\/doi.org\/10.1016\/j.jmii.2019.04.009 (2020).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"1257_CR148","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.3748\/wjg.v29.i32.4900","volume":"29","author":"HY Zhou","year":"2023","unstructured":"Zhou, H. Y. et al. Hepatitis B virus infection in patients with Wilson disease: a large retrospective study. World J. Gastroenterol. 29, 4900\u20134911 https:\/\/doi.org\/10.3748\/wjg.v29.i32.4900 (2023).","journal-title":"World J. Gastroenterol."},{"key":"1257_CR149","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.alcohol.2013.07.003","volume":"47","author":"M Zhang","year":"2013","unstructured":"Zhang, M., Wu, R., Jiang, J., Minuk, G. Y. & Niu, J. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis. Alcohol 47, 553\u2013558 https:\/\/doi.org\/10.1016\/j.alcohol.2013.07.003 (2013).","journal-title":"Alcohol"},{"key":"1257_CR150","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.dld.2014.07.172","volume":"46","author":"F Tandoi","year":"2014","unstructured":"Tandoi, F. et al. Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. Dig. Liver Dis. 46, 1020\u20131024 https:\/\/doi.org\/10.1016\/j.dld.2014.07.172 (2014).","journal-title":"Dig. Liver Dis."},{"key":"1257_CR151","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/liv.12980","volume":"36","author":"WK Seto","year":"2016","unstructured":"Seto, W.-K. et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int. 36, 642\u2013650 https:\/\/doi.org\/10.1111\/liv.12980 (2016).","journal-title":"Liver Int."},{"key":"1257_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/v13102053","volume":"13","author":"MC Kuhns","year":"2021","unstructured":"Kuhns, M. C. et al. Molecular and serological characterization of hepatitis B virus (HBV)-positive samples with very low or undetectable levels of HBV surface antigen. Viruses 13, 2053 https:\/\/doi.org\/10.3390\/v13102053 (2021).","journal-title":"Viruses"},{"key":"1257_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18609","volume":"9","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Evaluating the cost-effectiveness of low-level HBV DNA screening in occult hepatitis B infection donors: a study from Shandong Blood Center, China. Heliyon 9, e18609 https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18609 (2023).","journal-title":"Heliyon"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01257-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01257-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01257-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:03:29Z","timestamp":1789376609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01257-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":153,"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01257-x","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"21 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}